Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010–2015
Introduction: The National Comprehensive Cancer Network and the European Organization for Research and Treatment of Cancer recommend extracorporeal photopheresis (ECP) as systemic therapy for cutaneous T-cell lymphoma (CTCL). Objective: To investigate real-world use of ECP in CTCL patients in the US...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2019.1587144 |
| _version_ | 1797683709795631104 |
|---|---|
| author | You-Li Ling Xingyue Huang Ghaith Mitri Belinda Lovelace An Pham Robert Knobler Xiaocong Li Xin Gao |
| author_facet | You-Li Ling Xingyue Huang Ghaith Mitri Belinda Lovelace An Pham Robert Knobler Xiaocong Li Xin Gao |
| author_sort | You-Li Ling |
| collection | DOAJ |
| description | Introduction: The National Comprehensive Cancer Network and the European Organization for Research and Treatment of Cancer recommend extracorporeal photopheresis (ECP) as systemic therapy for cutaneous T-cell lymphoma (CTCL). Objective: To investigate real-world use of ECP in CTCL patients in the US. Methods: Data from the Truven MarketScan® database (2010–2015) were used to create a cohort of CTCL patients receiving systemic treatment. Multivariable regressions were performed to compare health care resource utilization between ECP and propensity score-matched non-ECP patients. Results: Of the 1106 eligible patients, 117 (10.6%) received ECP, with an average treatment duration of 13.6 months. Psoriasis, organ transplant, graft versus host disease, and scleroderma were the most common comorbidities. ECP was used as monotherapy in 76 patients (65.0%) and combination in 41 patients (35.0%), mostly with interferon and/or a retinoid. Higher Charlson Comorbidity Index (2.6 vs 2.2, p < .05), rates of organ transplant (49.6% vs 7.8%, p < .001), and graft vs host disease (41.9% vs 3.4%, p < .001) were observed in ECP versus non-ECP patients. Post-matching analyses showed that ECP patients had shorter all-cause inpatient stay (6.67 vs 11.80 days, p = .001). Conclusions: Approximately 1 out of 10 CTCL patients receiving systemic treatment were on ECP treatment in the US. Post-matching analysis showed ECP was associated with a shorter hospital stay. |
| first_indexed | 2024-03-12T00:18:29Z |
| format | Article |
| id | doaj.art-ce9545a40a274a2b98d2415982e49dd8 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:18:29Z |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-ce9545a40a274a2b98d2415982e49dd82023-09-15T14:08:34ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532020-01-01311919810.1080/09546634.2019.15871441587144Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010–2015You-Li Ling0Xingyue Huang1Ghaith Mitri2Belinda Lovelace3An Pham4Robert Knobler5Xiaocong Li6Xin Gao7Pharmerit International LPMallinckrodt PharmaceuticalsFormerly of Mallinckrodt PharmaceuticalsMallinckrodt PharmaceuticalsFormerly of Mallinckrodt PharmaceuticalsDepartment of Dermatology, Medical University of ViennaPharmerit International LPPharmerit International LPIntroduction: The National Comprehensive Cancer Network and the European Organization for Research and Treatment of Cancer recommend extracorporeal photopheresis (ECP) as systemic therapy for cutaneous T-cell lymphoma (CTCL). Objective: To investigate real-world use of ECP in CTCL patients in the US. Methods: Data from the Truven MarketScan® database (2010–2015) were used to create a cohort of CTCL patients receiving systemic treatment. Multivariable regressions were performed to compare health care resource utilization between ECP and propensity score-matched non-ECP patients. Results: Of the 1106 eligible patients, 117 (10.6%) received ECP, with an average treatment duration of 13.6 months. Psoriasis, organ transplant, graft versus host disease, and scleroderma were the most common comorbidities. ECP was used as monotherapy in 76 patients (65.0%) and combination in 41 patients (35.0%), mostly with interferon and/or a retinoid. Higher Charlson Comorbidity Index (2.6 vs 2.2, p < .05), rates of organ transplant (49.6% vs 7.8%, p < .001), and graft vs host disease (41.9% vs 3.4%, p < .001) were observed in ECP versus non-ECP patients. Post-matching analyses showed that ECP patients had shorter all-cause inpatient stay (6.67 vs 11.80 days, p = .001). Conclusions: Approximately 1 out of 10 CTCL patients receiving systemic treatment were on ECP treatment in the US. Post-matching analysis showed ECP was associated with a shorter hospital stay.http://dx.doi.org/10.1080/09546634.2019.1587144cutaneous t-cell lymphomamycosis fungoidesextracorporeal photopheresisreal-world usehealth care resource utilization |
| spellingShingle | You-Li Ling Xingyue Huang Ghaith Mitri Belinda Lovelace An Pham Robert Knobler Xiaocong Li Xin Gao Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010–2015 Journal of Dermatological Treatment cutaneous t-cell lymphoma mycosis fungoides extracorporeal photopheresis real-world use health care resource utilization |
| title | Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010–2015 |
| title_full | Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010–2015 |
| title_fullStr | Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010–2015 |
| title_full_unstemmed | Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010–2015 |
| title_short | Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010–2015 |
| title_sort | real world use of extracorporeal photopheresis for patients with cutaneous t cell lymphoma in the united states 2010 2015 |
| topic | cutaneous t-cell lymphoma mycosis fungoides extracorporeal photopheresis real-world use health care resource utilization |
| url | http://dx.doi.org/10.1080/09546634.2019.1587144 |
| work_keys_str_mv | AT youliling realworlduseofextracorporealphotopheresisforpatientswithcutaneoustcelllymphomaintheunitedstates20102015 AT xingyuehuang realworlduseofextracorporealphotopheresisforpatientswithcutaneoustcelllymphomaintheunitedstates20102015 AT ghaithmitri realworlduseofextracorporealphotopheresisforpatientswithcutaneoustcelllymphomaintheunitedstates20102015 AT belindalovelace realworlduseofextracorporealphotopheresisforpatientswithcutaneoustcelllymphomaintheunitedstates20102015 AT anpham realworlduseofextracorporealphotopheresisforpatientswithcutaneoustcelllymphomaintheunitedstates20102015 AT robertknobler realworlduseofextracorporealphotopheresisforpatientswithcutaneoustcelllymphomaintheunitedstates20102015 AT xiaocongli realworlduseofextracorporealphotopheresisforpatientswithcutaneoustcelllymphomaintheunitedstates20102015 AT xingao realworlduseofextracorporealphotopheresisforpatientswithcutaneoustcelllymphomaintheunitedstates20102015 |